Use of calcium channel blockers in cardiovascular risk reduction: Issues in Latin America

American Journal of Cardiovascular Drugs

Volumn 10, Issue 3, 2010, Pages 143-154

  Alcocer, Luis ^a   Bendersky, Mario ^b   Acosta, Julio ^c   Urina Triana, Miguel ^d  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c Policlinica Metropolitana   (Venezuela)

^d Fundación BIOS   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOPROLOL SUCCINATE; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; OLMESARTAN; PERINDOPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANTIOXIDANT ACTIVITY; ARTERY DISEASE; ATHEROSCLEROSIS; AWARENESS; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY DISEASE; DEVELOPED COUNTRY; DIABETES MELLITUS; DISEASE COURSE; DIZZINESS; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; ETHNIC DIFFERENCE; FLUSHING; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MONOTHERAPY; MORBIDITY; MORTALITY; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; STROKE; SYSTOLIC HYPERTENSION; TACHYCARDIA; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; VASCULARIZATION;

CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RISK REDUCTION BEHAVIOR;

EID: 77953246907     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11536120-000000000-00000     Document Type: Review

References (90)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991 Apr; 121 (4 Pt 1): 1244-1263
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289 (19): 2560-2572
3. Lanas F, Avezum A, Bautista LE, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007 Mar 6; 115 (9): 1067-1074
4. Piegas LS, Avezum A, Pereira JC, et al. Risk factors for myocardial infarction in Brazil. Am Heart J 2003 Aug; 146 (2): 331-338
5. Ciruzzi M, Schargrodsky H, Pramparo P, et al. Attributable risks for acute myocardial infarction in four countries of Latin America. Medicina (B Aires) 2003; 63 (6): 697-703
6. Touboul PJ, Hernandez-Hernandez R, Kucukoglu S, et al. Carotid artery intima media thickness, plaque and Framingham cardiovascular score in Asia, Africa/Middle East and Latin America: the PARC-AALA study. Int J Cardiovasc Imaging 2007 Oct; 23 (5): 557-567
7. Sanchez RA, Ayala M, Baglivo H, et al. Latin American guidelines on hypertension. J Hypertens 2009 May; 27 (5): 905-922
8. Lip GY, Makin AJ. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2003; (4): CD003075
9. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009 Jan 27; 119 (3): e21-181
10. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-1913
11. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21 (11): 1983-1992
12. Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment and control: continued disparities in adults. United States, 2005-2006. Hyattsville (MD): National Center for Health Statistics, NCHS Data Brief No. 3, 2008
13. Yach D, Hawkes C, Gould CL, et al. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004 Jun 2; 291 (21): 2616-2622
14. American Heart Association. International cardiovascular disease statistics: 2002 [online]. Available from URL: http://www.americanheart.org/down loadable/heart/1023898043312CVD-stats.pdf [Accessed 2009 Jan 19]
15. Cubillos-Garzon LA, Casas JP, Morillo CA, et al. Congestive heart failure in Latin America: the next epidemic. Am Heart J 2004 Mar; 147 (3): 412-417
16. Royer M, Castelo-Branco C, Blumel JE, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007 Apr; 10 (2): 164-170
17. Bustos P, da Silva AA, Amigo H, et al. Metabolic syndrome in young adults from two socioeconomic Latin American settings. Nutr Metab Cardiovasc Dis 2007 Oct; 17 (8): 581-589
18. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008 Apr; 263 (4): 336-352
19. Hernandez-Hernandez R, Armas-Padilla MC, Armas-Hernandez MJ, et al. Hypertension and cardiovascular health in Venezuela and Latin American countries. J Hum Hypertens 2000 Apr; 14 Suppl. 1: S2-5
20. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995 Mar; 25 (3): 305-313
21. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressurerelated disease, 2001. Lancet 2008 May 3; 371 (9623): 1513-1518
22. Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007 Dec 8; 370 (9603): 1929-1938
23. Ordunez P, Silva LC, Rodriguez MP, et al. Prevalence estimates for hypertension in Latin America and the Caribbean: are they useful for surveillance? Rev Panam Salud Publica 2001 Oct; 10 (4): 226-231 (Pubitemid 33064129)
24. Schargrodsky H, Hernandez-Hernandez R, Champagne BM, et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008 Jan; 121 (1): 58-65
25. Nigro D, Vergottini JC, Kuschnir E, et al. Epidemiología de la hipertensió n arterial en la ciudad de Có rdoba. Argentina Rev Fed Arg Cardiol 1999; 28: 1969-1975
26. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25 (9): 1751-1762
27. Consenso de Hipertensió n Arterial. Consejo Argentino de Hipertensión Arterial. Rev Arg Cardiol 2007; 75 Suppl. 3: 1-43
28. Ribeiro AB, Zanella MT, Kohlmann Jr O. Guidelines for treatment of hypertension in Latin America: the Brazilian experience. Clin Exp Hypertens 1999 Jul-Aug; 21 (5-6): 683-692
29. Burlando G, Sanchez RA, Ramos FH, et al. Latin American consensus on diabetes mellitus and hypertension. J Hypertens 2004 Dec; 22 (12): 2229-2241
30. Fuentes R, Ilmaniemi N, Laurikainen E, et al. Hypertension in developing economies: a review of population-based studies carried out from 1980 to 1998. J Hypertens 2000 May; 18 (5): 521-529
31. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997 May 17; 349 (9063): 1436-1442
32. Arredondo A, Zuniga A. Epidemiologic changes and economic burden of hypertension in Latin America: evidence fromMexico. Am J Hypertens 2006 Jun; 19 (6): 553-559
33. Rubinstein A, Alcocer L, Chagas A. High blood pressure in Latin America: a call to action. Ther Adv Cardiovasc Dis 2009; 3 (4): 259-285
34. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001 Mar; 14 (3): 241-247
35. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363 (9426): 2022-2031
36. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000 Jul 29; 356 (9227): 366-372
37. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000 Jul 29; 356 (9227): 359-365
38. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003 Apr 23-30; 289 (16): 2073-2082
39. Dubois C, Blanchard D. Efficacy and safety of nicardipine in 29,104 patients with hypertension. Clin Ther 1989 Jul-Aug; 11 (4): 452-460
40. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of theHypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-1762 (Pubitemid 28269185)
41. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13; 350 (9080): 757-764
42. Pastor-Barriuso R, Banegas JR, Damian J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003 Nov 4; 139 (9): 731-739
43. Lawes CM, Vander Hoorn S, Law MR, et al. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006 Mar; 24 (3): 423-430 (Pubitemid 43261901)
44. Mancia G, Ruilope L, Palmer C, et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension: a subanalysis of the INSIGHT study. Blood Press 2004; 13 (5): 310-315
45. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000 Dec 9; 356 (9246): 1955-1964
46. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002 Dec 18; 288 (23): 2981-2997
47. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or coamilozide in hypertensive diabetics and nondiabetics in Intervention as aGoal in Hypertension (INSIGHT). Hypertension 2003 Mar; 41 (3): 431-436
48. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10-16; 366 (9489): 895-906
49. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359 (23): 2417-2428
50. Kuschnir E, BenderskyM, Resk J, et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 2004 Feb; 43 (2): 300-305
51. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008 Apr; 30 (4): 587-604
52. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 Apr; 29 (4): 563-580
53. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICECombi (Nifedipine and Candesartan Combination) study. J Hypertens 2005 Feb; 23 (2): 445-453
54. Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) study. Hypertens Res 2006 Oct; 29 (10): 789-796
55. Frishman WH, Hainer JW, Sugg J. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Am J Hypertens 2006 Apr; 19 (4): 388-395
56. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST) - a randomized controlled trial. JAMA2003Dec 3; 290 (21): 2805-2816
57. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study - a randomized controlled trial. JAMA 2004 Nov 10; 292 (18): 2217-2225
58. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004 Sep 4-10; 364 (9437): 849-857
59. Mancia G. The TALENT study. Eur Cardiol Extract Touch Brief 2008; 4 (1): 75-78
60. Messerli FH, Noll G, Lindholm LH, et al. The role of dihydropyridine calcium channel blockers in the treatment of hypertension and cardiovascular diseasean update. Eur Cardiovasc Dis 2006: 16-20
61. Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005 Mar; 23 (3): 641-648
62. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 Jan 11; 295 (2): 180-189
63. Taddei S, Virdis A, Ghiadoni L, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001 Mar; 37 (3): 943-948
64. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003 Jun; 41 (6): 1281-1286
65. Noronha-Dutra AA, Steen-Dutra EM, Woolf N. An antioxidant role for calcium antagonists in the prevention of adrenaline mediated myocardial and endothelial damage. Br Heart J 1991 Jun; 65 (6): 322-325
66. Verhaar MC, Honing ML, van Dam T, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999 Jun; 42 (3): 752-760
67. The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease. Circulation 2003 Jan 28; 107 (3): 422-428
68. Luscher TF, Pieper M, Tendera M, et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009 Jul; 30 (13): 1590-1597
69. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996 Sep 11; 276 (10): 785-791
70. Zanchetti A, Rosei EA, Dal Palu C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998 Nov; 16 (11): 1667-1676
71. Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and coamilozide on the progression of early carotid wall changes. Circulation 2001 Jun 19; 103 (24): 2949-2954
72. Jukema JW, Zwinderman AH, van Boven AJ, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol 1996 Mar; 16 (3): 425-430
73. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990 May 12; 335 (8698): 1109-1113 (Pubitemid 20159424)
74. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001 Jun; 37 (6): 1410-1413
75. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep 26; 102 (13): 1503-1510
76. Shinoda E, Yui Y, Kodama K, et al. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005 Jun; 45 (6): 1153-1158
77. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995 Jan 15; 122 (2): 133-141
78. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004 Dec 13-27; 164 (22): 2459-2464
79. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000 Mar 30; 342 (13): 905-912
80. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004 Nov 4; 351 (19): 1941-1951
81. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106 (6): 672-678
82. Baba S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001 Dec; 54 (3): 191-201
83. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensinconverting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000 Feb; 57 (2): 590-600
84. Tatti P, PahorM, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998 Apr; 21 (4): 597-603
85. Scognamiglio R, Nosadini R, Marin M, et al. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients. Diabetes Care 1997 Aug; 20 (8): 1290-1292
86. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996 Feb; 45 (2): 216-222
87. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005; (4): CD004136
88. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000 Dec 1; 86 (11): 1182-1187
89. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 Jan 20; 369 (9557): 201-207
90. Alcocer L, Parra JZ, Herná ndez HH. Una versió n minimalista sobre el tratamiento de la hipertensió n arterial: esquemas de tratamiento antihipertensor. Rev Mex Cardiol 2008; 19: 3-6